![Stefan Luzi](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Stefan Luzi
Direktor/Vorstandsmitglied bei Amphista Therapeutics Ltd.
Profil
Stefan Luzi is currently a Non-Executive Director at Amphista Therapeutics Ltd.
and a Partner at Gilde Healthcare Partners BV.
Previously, he served as a Non-Executive Director at LAVA Therapeutics NV from 2018 to 2023 and as a Director at Draupnir Bio ApS.
Dr. Luzi holds a graduate and doctorate degree from the University of Cambridge and undergraduate and graduate degrees from the Swiss Federal Institute of Technology.
Aktive Positionen von Stefan Luzi
Unternehmen | Position | Beginn |
---|---|---|
Gilde Healthcare Partners BV
![]() Gilde Healthcare Partners BV Investment ManagersFinance Gilde Healthcare Partners BV is a Private Equity/Venture Capital firm, a subsidiary of Gilde Healthcare Holding BV founded in 1999 by Pieter van der Meer and Edwin William de Graaf. Gilde Healthcare Partners BV is headquartered in Utrecht with additional office in Cambridge. | Private Equity Investor | 01.08.2017 |
Amphista Therapeutics Ltd.
![]() Amphista Therapeutics Ltd. BiotechnologyHealth Technology Amphista Therapeutics Ltd. is a biopharmaceutical company based in Biocity Glasgow, UK. The British company is focused on creating first-in-class therapeutics that selectively and efficiently degrade and remove disease-causing proteins using targeted protein degradation (TPD). The company's pipeline of novel small molecules is focused on challenging diseases, including cancer. Amphista is a spin-out of Professor Alessio Ciulli's labs at the University of Dundee and is funded by leading life science investors, including Advent Life Sciences, the European Investment Fund, the Scottish Investment Bank, and Biomotiv. The CEO of the company is Nicola Thompson. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Stefan Luzi
Unternehmen | Position | Ende |
---|---|---|
LAVA THERAPEUTICS N.V. | Direktor/Vorstandsmitglied | 09.03.2023 |
Draupnir Bio ApS
![]() Draupnir Bio ApS Pharmaceuticals: MajorHealth Technology Draupnir Bio ApS engages in the manufacture and distribution of biotechnological and pharmaceutical products. It also provides medical research services. The company was founded on April 4, 2017 and is headquartered in Risskov, Denmark. | Direktor/Vorstandsmitglied | - |
Ausbildung von Stefan Luzi
Swiss Federal Institute of Technology | Graduate Degree |
University of Cambridge | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
LAVA THERAPEUTICS N.V. | Health Technology |
Private Unternehmen | 3 |
---|---|
Gilde Healthcare Partners BV
![]() Gilde Healthcare Partners BV Investment ManagersFinance Gilde Healthcare Partners BV is a Private Equity/Venture Capital firm, a subsidiary of Gilde Healthcare Holding BV founded in 1999 by Pieter van der Meer and Edwin William de Graaf. Gilde Healthcare Partners BV is headquartered in Utrecht with additional office in Cambridge. | Finance |
Draupnir Bio ApS
![]() Draupnir Bio ApS Pharmaceuticals: MajorHealth Technology Draupnir Bio ApS engages in the manufacture and distribution of biotechnological and pharmaceutical products. It also provides medical research services. The company was founded on April 4, 2017 and is headquartered in Risskov, Denmark. | Health Technology |
Amphista Therapeutics Ltd.
![]() Amphista Therapeutics Ltd. BiotechnologyHealth Technology Amphista Therapeutics Ltd. is a biopharmaceutical company based in Biocity Glasgow, UK. The British company is focused on creating first-in-class therapeutics that selectively and efficiently degrade and remove disease-causing proteins using targeted protein degradation (TPD). The company's pipeline of novel small molecules is focused on challenging diseases, including cancer. Amphista is a spin-out of Professor Alessio Ciulli's labs at the University of Dundee and is funded by leading life science investors, including Advent Life Sciences, the European Investment Fund, the Scottish Investment Bank, and Biomotiv. The CEO of the company is Nicola Thompson. | Health Technology |